NCT00925730View on ClinicalTrials.gov

Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

January 31, 2006

Conditions
Atopic Dermatitis
Interventions
DRUG

Pimecrolimus

Trial Locations (2)

Unknown

Novartis Investigative Site, Bonn

Novartis Investigative Site, Frankfurt am Main

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00925730 - Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion | Biotech Hunter | Biotech Hunter